Skip to main content

Advertisement

Table 1 Characteristics of Helicobacter pylori positive and negative patients

From: Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

  H. pylori positive, n = 179 H. pylori negative, n = 824 p-value*
Age, years 66.2 ± 8.5 65.3 ± 8.7 0.18
Male sex 118 (65.9) 485 (58.9) 0.08
Current smoker 36 (20.1) 175 (21.3) 0.73
Smoking history - Pack years 58.5 ± 32.5 58.3 ± 31.8 0.94
Ethnicity (Caucasian) 112 (62.6) 716 (86.9) <0.001
Peptic ulcer history 36 (20.1) 102 (12.4) 0.006
Dyspnea (MRC grade) 1.55 ± 0.89 1.53 ± 0.91 0.78
Hospitalization for COPD past year 80 (44.7) 423 (51.3) 0.11
FEV1, Liter 1.1 ± 0.5 1.1 ± 0.5 0.25
FEV1, % predicted 38.5 ± 15.1 39.9 ± 15.7 0.27
FVC, Liter 2.5 ± 0.8 2.7 ± 0.9 0.07
FVC, % predicted 67.8 ± 16.4 70.7 ± 18.3 0.049
FEV1/FVC % 42.5 ± 12.2 42.6 ± 12.8 0.97
GOLD grade, n (%)    0.65
 II 42 (23.5) 216 (26.3)  
 III 75 (41.9) 344 (42.0)  
 IV 62 (34.6) 260 (31.7)  
Baseline biomarker data    
 CRP (mg/L) 4.83 ± 3.89 4.91 ± 3.87 0.80
 sTNFR75 (μg/L) 8.79 ± 4.41 8.71 ± 4.87 0.85
  1. Data are presented as means ± standard deviation or absolute number (%)
  2. MRC medical research council, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, CRP C-reactive protein, sTNFR75 soluble tumor necrosis factor receptor-75
  3. *Unpaired t-test or Chi-square test
  4. The results of FEV1, FVC, and FEV1/FVC are post-bronchodilator values